Abstract
The SARS-COV-2 virus is a deadly agent of inflammatory respiratory disease. Since 2020, studies have focused on developing new therapies based on galactose-rich IgA antibodies. Clinical surveys have also revealed that galactose-deficient IgA1 polymerizes in serum, producing IgA nephropathy, which is a common cause of kidney failure in young adults. Here we show that IgA1-IgA2 dimers are efficiently and economically purified in solution via conjugated nonionic surfactant micellar aggregates. Quantitative capture at pH 7 and extraction at pH 6.5 can avoid antibody exposure to acidic, potentially denaturing conditions. Brij-O20 aggregates lead to the highest process yields (88-91%) and purity (94%). Recovered IgA dimers preserve their native secondary structure and do not self-associate. Increasing the reaction volume has little impact on yield or purity. By introducing an efficient, inexpensive IgA purification protocol, we assist pharmaceutical firms and research laboratories in developing new IgA-based therapies as well as in increasing our understanding of IgA1 polymerization.
Original language | English |
---|---|
Pages (from-to) | 979-986 |
Number of pages | 8 |
Journal | ACS Medicinal Chemistry Letters |
Volume | 15 |
Issue number | 6 |
DOIs | |
Publication status | Published Online - 15 May 2024 |
Funding
G.P. thanks Dr. Shira Albeck from the Israel Structural Proteomic Center at the Weizmann Institute of Science and Ariel University for its support. Publisher Copyright: © 2024 American Chemical Society.
All Science Journal Classification (ASJC) codes
- Biochemistry
- Drug Discovery
- Organic Chemistry